Affinity Asset Advisors LLC Increases Position in Trevi Therapeutics, Inc. $TRVI

Affinity Asset Advisors LLC lifted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 102.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,534,058 shares of the company’s stock after buying an additional 1,284,058 shares during the quarter. Trevi Therapeutics makes up about 1.9% of Affinity Asset Advisors LLC’s portfolio, making the stock its 15th biggest position. Affinity Asset Advisors LLC’s holdings in Trevi Therapeutics were worth $13,861,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Trevi Therapeutics by 9.4% during the 1st quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company’s stock valued at $24,141,000 after acquiring an additional 328,819 shares during the period. MPM Bioimpact LLC lifted its position in shares of Trevi Therapeutics by 10.8% during the first quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company’s stock worth $21,564,000 after purchasing an additional 333,470 shares during the last quarter. Octagon Capital Advisors LP purchased a new stake in shares of Trevi Therapeutics during the first quarter valued at $20,895,000. Armistice Capital LLC bought a new position in shares of Trevi Therapeutics in the first quarter worth about $18,795,000. Finally, Acorn Capital Advisors LLC increased its stake in Trevi Therapeutics by 7.2% in the 1st quarter. Acorn Capital Advisors LLC now owns 2,144,844 shares of the company’s stock worth $13,491,000 after buying an additional 143,796 shares during the period. 95.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

TRVI has been the subject of a number of research analyst reports. B. Riley upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, November 17th. Needham & Company LLC decreased their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, October 8th. Leerink Partners raised their price objective on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, Morgan Stanley lifted their target price on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $21.44.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $13.47 on Friday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -36.40 and a beta of 0.83. Trevi Therapeutics, Inc. has a 52-week low of $2.36 and a 52-week high of $14.00. The company’s 50 day moving average is $11.07 and its 200 day moving average is $8.43.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.02. Analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.